With a price-to-earnings (or "P/E") ratio of 19x China Resources Medical Holdings Company Limited (HKG:1515) may be sending very bearish signals at the moment, given that almost half of all companies in Hong Kong have P/E ratios under 9x and even P/E's lower than 4x are not unusual. However, the P/E might be quite high for a reason and it requires further investigation to determine if it's justified.
China Resources Medical Holdings has been struggling lately as its earnings have declined faster than most other companies. It might be that many expect the dismal earnings performance to recover substantially, which has kept the P/E from collapsing. If not, then existing shareholders may be very nervous about the viability of the share price.
Check out our latest analysis for China Resources Medical Holdings
Keen to find out how analysts think China Resources Medical Holdings' future stacks up against the industry? In that case, our free report is a great place to start.
How Is China Resources Medical Holdings' Growth Trending?
The only time you'd be truly comfortable seeing a P/E as steep as China Resources Medical Holdings' is when the company's growth is on track to outshine the market decidedly.
If we review the last year of earnings, dishearteningly the company's profits fell to the tune of 37%. The last three years don't look nice either as the company has shrunk EPS by 10% in aggregate. So unfortunately, we have to acknowledge that the company has not done a great job of growing earnings over that time.
Looking ahead now, EPS is anticipated to climb by 43% per year during the coming three years according to the six analysts following the company. That's shaping up to be materially higher than the 16% each year growth forecast for the broader market.
In light of this, it's understandable that China Resources Medical Holdings' P/E sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.
What We Can Learn From China Resources Medical Holdings' P/E?
Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
As we suspected, our examination of China Resources Medical Holdings' analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. It's hard to see the share price falling strongly in the near future under these circumstances.
You should always think about risks. Case in point, we've spotted 1 warning sign for China Resources Medical Holdings you should be aware of.
Of course, you might also be able to find a better stock than China Resources Medical Holdings. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
China Resources Medical Holdings(HKG:1515)の株価収益率(P/E)比率が19倍であるため、ほぼすべての香港企業の半数が9倍未満のP/E比率を持ち、4倍未満のP/E比率も珍しくありませんので、現時点で非常に弱気なシグナルを発している可能性があります。しかし、P/E比率が高い理由は、正当化されるかどうかを判断するためにさらなる調査が必要です。
本社の収益が他社よりも速く減少しているため、China Resources Medical Holdingsは最近苦戦しているかもしれません。多くの人々が本需要の収益性の悪さが大幅に改善することを期待している可能性がありますが、それが崩壊しないようにしているのかもしれません。そうでない場合、株主は株価の持続可能性について非常に不安を感じるかもしれません。
China Resources Medical Holdingsの最新分析をチェックしてください。
アナリストはChina Resources Medical Holdingsの将来が業種とどのように競合しているかを調査している場合、無料レポートが良いスタート地点となります。
China Resources Medical Holdingsの成長はどのように進んでいますか?
China Resources Medical HoldingsのP/E比率が急上昇しているシーンは、会社の成長が市場を決定的に上回っている場合だけです。
予想通り、China Resources Medical Holdingsのアナリスト予測の調査から、高いP/Eに貢献している優れた収益性の見通しが明らかになりました。現在、株主はP/Eに快適なため、将来の収益に脅威がないと信じています。結局のところ、これらの状況では株価が急落するのを予想するのは困難です。
リスクについて常に考えるべきです。事実、China Resources Medical Holdingsの警告が1つ見つかりました。
もちろん、China Resources Medical HoldingsよりP/E比率が合理的で収益が強く成長した他の企業の無料のコレクションを参照することもできます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会(ASIC)の管理を受けております(AFSL No. 224663)。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会(ASIC)の管理を受けております(AFSL No. 224663)。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。